Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)

  • Cancer
  • Non-Hodgkin's Lymphoma
  • Diffuse Large B-Cell Lymphoma (DLBCL)
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
City
  • Marlow
Trial Identifier:

NCT02708732 ML29956

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This study is a prospective, cross-sectional survey to be administered to real patients in remission from DLBCL using a 15-minute postal or online survey. The project is designed to describe the impact of DLBCL remission on health utility and quality of life. Data collection will occur over a 4-month period.

      Hoffmann-La Roche Sponsor
      NCT02708732,ML29956 Trial Identifier
      Diffuse Large B-Cell Lymphoma Condition
      Official Title

      UK Utility Study in Diffuse Large B-Cell Lymphoma

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Adults greater than or equal to (>/=) 18 years of age
      • Diagnosis of DLBCL and currently in first remission
      • Prior drug treatment for DLBCL
      Exclusion Criteria
      • Receiving active treatment for DLBCL
      • Relapsed following any treatment for DLBCL

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now